Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
02 05 2019
Historique:
received: 02 04 2018
accepted: 17 08 2018
pubmed: 24 8 2018
medline: 23 7 2020
entrez: 24 8 2018
Statut: ppublish

Résumé

AIDS Clinical Trial Group 5199 compared neurological and neuropsychological test performance of human immunodeficiency virus type 1 (HIV-1)-infected participants in resource-limited settings treated with 3 World Health Organization-recommended antiretroviral (ART) regimens. We investigated the impact of tuberculosis (TB) on neurological and neuropsychological outcomes. Standardized neurological and neuropsychological examinations were administered every 24 weeks. Generalized estimating equation models assessed the association between TB and neurological/neuropsychological performance. Characteristics of the 860 participants at baseline were as follows: 53% female, 49% African; median age, 34 years; CD4 count, 173 cells/μL; and plasma HIV-1 RNA, 5.0 log copies/mL. At baseline, there were 36 cases of pulmonary, 9 cases of extrapulmonary, and 1 case of central nervous system (CNS) TB. Over the 192 weeks of follow-up, there were 55 observations of pulmonary TB in 52 persons, 26 observations of extrapulmonary TB in 25 persons, and 3 observations of CNS TB in 2 persons. Prevalence of TB decreased with ART initiation and follow-up. Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01). TB was associated with diffuse CNS disease (P < .05). Furthermore, those with TB had 9.27 times (P < .001) higher odds of reporting decreased quality of life, and had 8.02 times (P = .0005) higher odds of loss of productivity. TB coinfection was associated with poorer neuropsychological functioning, particularly the fine motor skills, and had a substantial impact on functional ability and quality of life. NCT00096824.

Sections du résumé

BACKGROUND
AIDS Clinical Trial Group 5199 compared neurological and neuropsychological test performance of human immunodeficiency virus type 1 (HIV-1)-infected participants in resource-limited settings treated with 3 World Health Organization-recommended antiretroviral (ART) regimens. We investigated the impact of tuberculosis (TB) on neurological and neuropsychological outcomes.
METHODS
Standardized neurological and neuropsychological examinations were administered every 24 weeks. Generalized estimating equation models assessed the association between TB and neurological/neuropsychological performance.
RESULTS
Characteristics of the 860 participants at baseline were as follows: 53% female, 49% African; median age, 34 years; CD4 count, 173 cells/μL; and plasma HIV-1 RNA, 5.0 log copies/mL. At baseline, there were 36 cases of pulmonary, 9 cases of extrapulmonary, and 1 case of central nervous system (CNS) TB. Over the 192 weeks of follow-up, there were 55 observations of pulmonary TB in 52 persons, 26 observations of extrapulmonary TB in 25 persons, and 3 observations of CNS TB in 2 persons. Prevalence of TB decreased with ART initiation and follow-up. Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01). TB was associated with diffuse CNS disease (P < .05). Furthermore, those with TB had 9.27 times (P < .001) higher odds of reporting decreased quality of life, and had 8.02 times (P = .0005) higher odds of loss of productivity.
CONCLUSIONS
TB coinfection was associated with poorer neuropsychological functioning, particularly the fine motor skills, and had a substantial impact on functional ability and quality of life.
CLINICAL TRIALS REGISTRATION
NCT00096824.

Identifiants

pubmed: 30137250
pii: 5076927
doi: 10.1093/cid/ciy718
pmc: PMC6495021
doi:

Banques de données

ClinicalTrials.gov
['NCT00096824']

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1739-1746

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069518
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069432
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069471
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069481
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069518
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069426
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009608
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW001081
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069417
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069424
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106701
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069476
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069424
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069438
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069399
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068636
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069463
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069401
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

PLoS One. 2013;8(2):e54145
pubmed: 23408935
J Neurovirol. 2016 Aug;22(4):472-8
pubmed: 26733457
Ann Neurol. 1993 Apr;33(4):343-9
pubmed: 8489204
Neurology. 1993 Nov;43(11):2245-52
pubmed: 8232937
Lancet. 2002 Jun 15;359(9323):2059-64
pubmed: 12086758
Semin Neurol. 1992 Mar;12(1):18-27
pubmed: 1615236
Continuum (Minneap Minn). 2012 Dec;18(6 Infectious Disease):1319-37
pubmed: 23221843
PLoS One. 2012;7(1):e29775
pubmed: 22253777
J Neurovirol. 2011 Oct;17(5):438-47
pubmed: 21786076
J Neurol. 2011 Jan;258(1):3-13
pubmed: 20848123
Lancet. 2010 May 29;375(9729):1906-19
pubmed: 20488516
J Acquir Immune Defic Syndr (1988). 1990;3 Suppl 2:S51-60
pubmed: 2231303
PLoS Med. 2012;9(8):e1001290
pubmed: 22936892
J Infect Dis. 2008 May 15;197 Suppl 3:S294-306
pubmed: 18447615
Ann Neurol. 1986 Jun;19(6):525-35
pubmed: 3014994
Semin Neurol. 2014 Feb;34(1):103-15
pubmed: 24715493
J Infect. 2009 Sep;59(3):156-66
pubmed: 19635500
PLoS One. 2013 May 31;8(5):e64915
pubmed: 23741419
Int J Tuberc Lung Dis. 2013 Mar;17(3):345-7
pubmed: 23321341
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Malays J Med Sci. 2014 Jan;21(1):4-10
pubmed: 24639606
Ann Neurol. 1986 Jun;19(6):517-24
pubmed: 3729308
BMC Med. 2013 Dec 02;11:253
pubmed: 24295487
Eur J Neurol. 2007 Jan;14(1):33-7
pubmed: 17222110
Neurology. 1991 Jun;41(6):778-85
pubmed: 2046917
Ann Neurol. 1988;23 Suppl:S4-6
pubmed: 2831802
PLoS One. 2007 Sep 05;2(9):e826
pubmed: 17786198

Auteurs

Kevin R Robertson (KR)

AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.

Bibilola Oladeji (B)

University of Ibadan, Nigeria.

Hongyu Jiang (H)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Johnstone Kumwenda (J)

Queen Elizabeth, Blantyre, Malawi.

Khuanchai Supparatpinyo (K)

Chiang Mai University, Thailand.

Thomas B Campbell (TB)

University of Colorado Health Sciences Center, Denver.

James Hakim (J)

University of Zimbabwe, Harare, Zimbabwe.

Srikanth Tripathy (S)

National AIDS Research Institute, Pune, India.

Mina C Hosseinipour (MC)

Lilongwe, Malawi.

Christina M Marra (CM)

University of Washington, Seattle.

Nagalingeswaran Kumarasamy (N)

Gaitonde Centre for AIDS Research and Education, Chennai, India.

Scott Evans (S)

Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Alyssa Vecchio (A)

Vita-Salute San Raffaele University, Milan, Italy.

Alberto La Rosa (A)

Asociacion Civil Impacta Salud y Educacion,Lima, Peru.

Breno Santos (B)

Hospital Conceicao, Porto Alegre Porto Alegre.

Marcus T Silva (MT)

Fiocruz, Rio De Janeiro, Brazil.

Sylvia Montano (S)

Asociacion Civil Impacta Salud y Educacion,Lima, Peru.

Cecilia Kanyama (C)

Lilongwe, Malawi.

Cindy Firnhaber (C)

Johannesburg, South Africa.

Richard Price (R)

University of California San Francisco.

Cheryl Marcus (C)

AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.

Baida Berzins (B)

Northwestern University, Chicago, Illinois.

Reena Masih (R)

Social Scientific Systems, Silver Springs, Maryland.

Umesh Lalloo (U)

Durban, South Africa.

Ian Sanne (I)

Johannesburg, South Africa.

Sarah Yosief (S)

AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.

Ann Walawander (A)

Frontier Science & Technology Research Foundation, Buffalo, New York.

Aspara Nair (A)

Frontier Science & Technology Research Foundation, Buffalo, New York.

Ned Sacktor (N)

Johns Hopkins University, Baltimore.

Colin Hall (C)

AIDS Neurological Center, Neurology, University of North Carolina, Chapel Hill.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH